Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABBV 011 (Primary) ; Budigalimab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors AbbVie

Most Recent Events

  • 06 Jun 2023 Preliminary results (n=99; at data cutoff date: 22 Aug 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 01 Jun 2023 According to a Sarah Cannon Research Institute media release, data from this trial will be presented in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Patients with Small Cell Lung Cancer, on June 5 at 8 a.m. CDT in Hall D2.
  • 15 May 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top